Glumet

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glumet

What is Glumet?

Glumet is an oral medication categorized as a biguanide. It is primarily used in the management of type 2 diabetes mellitus, a chronic condition where the body does not use insulin normally and cannot control the amount of sugar in the blood.

Mechanism of Action

Glumet works by addressing how the body handles glucose (blood sugar). It does not increase the production of insulin; instead, it focuses on improving the body’s response to the insulin it already produces. The medication functions through three primary mechanisms:

  • Reducing Hepatic Glucose Production: It limits the amount of glucose that the liver releases into the bloodstream.
  • Improving Insulin Sensitivity: It enhances the ability of muscle and fat tissues to take up and utilize existing insulin more effectively.
  • Slowing Intestinal Absorption: It decreases the rate at which glucose is absorbed from the digestive tract after eating.

Clinical Purpose

The fundamental goal of Glumet therapy is to help maintain blood glucose levels within a target range. By lowering both basal (resting) and postprandial (after-meal) blood sugar levels, the medication assists in the long-term management of glycemic control.

Unlike some other glucose-lowering medications, Glumet is generally associated with a low risk of hypoglycemia (excessively low blood sugar) when used as a standalone therapy, as it does not stimulate the pancreas to secrete additional insulin.

What side effects are possible with Glumet?

Glumet: Possible Side Effects and Safety Information

Adverse effects documented for Metformin Hydrochloride are classified by frequency and grouped into System-Organ Classes according to regulatory standards.


Adverse Reaction Classifications

The most commonly reported adverse reactions are Gastrointestinal Disorders, which are classified as Very Common (ge 1/10). These include diarrhoea, nausea, vomiting, abdominal pain, and loss of appetite. These effects are often most noticeable at the start of treatment and are generally transient.

A Common side effect (ge 1/100 to <1/10) is taste disturbance, typically described as a metallic taste.

Serious Safety Considerations

The most significant safety concern documented in regulatory labeling is Lactic Acidosis, classified as Very Rare (<1/10,000). Lactic acidosis is a severe, potentially life-threatening metabolic complication. The risk of this serious reaction is substantially increased in the presence of certain limiting conditions.

Very Rare reactions also include abnormalities in liver function, reports of hepatitis, and skin reactions such as urticaria, pruritus, and erythema. Long-term use is associated with a decrease in Vitamin B12 absorption, which may lead to clinically relevant deficiency or megaloblastic anaemia.


Population- and Organ-Specific Safety

Metformin is subject to explicit safety restrictions related to organ function. It is contraindicated in patients with severe renal impairment, typically defined as an estimated glomerular filtration rate ( eGFR) below 30 mL/ min/1.73 m^2, as this significantly raises the risk of drug accumulation and subsequent lactic acidosis. Use is also restricted in cases of hepatic impairment and conditions associated with tissue hypoxia (e.g., heart or respiratory failure), as these states also potentiate the serious risk. Assessment of renal status is particularly important for older adults.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Glumet (Metformin Hydrochloride) overdose focuses strictly on the risk of Metformin-Associated Lactic Acidosis (MALA). Lactic acidosis is a rare but life-threatening complication documented in regulatory labeling, which can lead to severe systemic outcomes including cardiovascular collapse, coma, and death.

Documented Manifestations and Emergency Actions

Domain Regulatory-Documented Information
Clinical Presentations Nonspecific symptoms that may precede severe overdose include malaise, muscle pain (myalgias), increasing somnolence, respiratory distress, and abdominal pain. Advanced signs are hypotension and hypothermia.
Required Medical Action Lactic acidosis must be managed as a medical emergency in a hospital setting. The drug must be immediately discontinued upon suspicion of this condition.
Life-Threatening Outcomes The condition carries a high risk of fatality; severe cases may lead to cardiovascular collapse and coma.

The official guidance instructs patients to seek immediate medical attention and promptly report any of these nonspecific symptoms to a healthcare provider. In confirmed overdose cases, regulatory documents specify that prompt hemodialysis is recommended to remove the accumulated metformin and correct the acidosis. Regulatory information confirms no specific antidotes are available to reverse the effects of Glumet overdose. The risk of accumulation is higher in patients with renal impairment and those aged 65 years or greater.

Therapeutic Uses of Glumet

Glumet: Main Uses and Support

Glumet is an established prescription medication used to help manage blood sugar levels in adults and children (aged 10 years and older) who have type 2 diabetes mellitus. This agent is intended to be used in conjunction with appropriate lifestyle measures, including diet and physical activity, to support adequate glycemic control.

Controlling blood sugar is an essential element of diabetes management. Glumet may help patients sustain blood sugar within a target range, which is part of a plan to reduce the potential for long-term complications associated with type 2 diabetes, such as kidney and eye concerns. It is one option for monotherapy and can also be used in combination with other therapeutic agents, including insulin, as part of a comprehensive care regimen.

In some instances, Glumet may be used to support the management of symptoms associated with polycystic ovary syndrome (PCOS).


Quick Facts (Therapeutic Domains Only)

  • Helps manage blood sugar levels in type 2 diabetes mellitus.
  • Supports adequate glycemic control when used with diet and exercise.
  • May be used to support the management of symptoms in polycystic ovary syndrome (PCOS).

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults and pediatric patients 10 years and older with Type 2 Diabetes Mellitus.

Populations for whom use is contraindicated:

  • Patients with Severe Renal Impairment (eGFR below 30 mL/min/1.73 m²).
  • Patients with Acute or Chronic Metabolic Acidosis, including Diabetic Ketoacidosis.
  • Patients with known Hypersensitivity to the active ingredient or any component.
  • Patients with Hepatic Insufficiency or acute conditions causing Tissue Hypoxia (e.g., Unstable Heart Failure, Severe Respiratory Failure).

Eligibility-related restrictions:

  • Moderate Renal Impairment (eGFR 30 to 45 mL/min/1.73 m²) is a major limitation for initiation.
  • The medicine must be temporarily discontinued at the time of, or prior to, radiological procedures involving iodinated contrast agents or elective surgery involving anesthesia.
  • Use is not recommended in children under 10 years of age, women who are Lactating, or patients with a history of Excessive Alcohol Intake.

Eligibility Classifications (High-Level)

Eligibility severity classification:

  • Contraindicated (Absolute Non-Eligibility).
  • Not Recommended (Conditional or Restricted Use).

Connection to the overall eligibility profile: Official regulatory documents define eligibility based on age (10 years and older) and primarily structured by strict exclusions tied to organ function and disease severity. The majority of non-eligibility rules relate to the status of renal and hepatic function, the presence of metabolic or hypoxic conditions, and mandatory temporary cessation requirements for specific procedures.

What should I know about interactions with other medicines?

The official regulatory documents for Glumet (Metformin Hydrochloride) define its interaction profile through effects on drug clearance, glycemic control, and metabolic risk. The most severe restrictions involve Iodinated Contrast Media, requiring the mandatory discontinuation of Glumet at the time of or prior to the procedure, and being withheld for 48 hours subsequent to the procedure. Glumet is also contraindicated in conditions such as severe renal impairment (eGFR below 30 mL/min/1.73 m^2) and acute metabolic acidosis.

Interaction Category Specific Substance/Condition Regulatory Outcome
Pharmacokinetic Cimetidine and other Cationic Active Substances May delay elimination by competing for renal tubular transport systems, increasing Glumet's systemic exposure (AUC). Ranolazine, Vandetanib, and Dolutegravir may similarly increase drug accumulation.
Pharmacodynamic Insulin and Insulin Secretagogues Concomitant use carries an officially documented increased risk of hypoglycemia due to additive effects. Carbonic Anhydrase Inhibitors may increase the risk of lactic acidosis.

Substance and Population Notes

Excessive Alcohol intake is documented to potentiate Glumet's effect on lactate metabolism. Glumet may also officially lower serum Vitamin B12 levels. For geriatric patients, the label notes the need for more frequent renal function assessment due to the increased risk of drug accumulation linked to age-related decline in clearance.

Mechanism of Action

Mechanism of Action

Glumet exerts its primary effect through the inhibition of mitochondrial complex I in the liver, a component of the cellular respiratory chain. This inhibition alters the intracellular energy state, leading to the activation of AMP-activated protein kinase (AMPK). Activated AMPK acts as a key metabolic sensor, suppressing the transcription and activity of enzymes necessary for hepatic gluconeogenesis (new glucose production). This cascade results in a reduction of glucose output released by the liver into the systemic circulation.

Beyond the liver, Glumet's activation of AMPK promotes the translocation of GLUT4 glucose transporters to the cell surface, particularly in muscle tissue. This action increases the efficiency of peripheral cells to utilize glucose from the blood, contributing to increased peripheral glucose clearance. Furthermore, the drug causes a modest reduction in the rate of glucose absorption from the gastrointestinal tract, resulting in a reduced rate of glucose influx into the bloodstream following a meal.

Dosage and Administration Information

Official Administration Guidelines

Glumet (Metformin Hydrochloride) is approved for oral administration and is available in both immediate-release (IR) and extended-release (ER) formulations. The medicine is administered based on a gradual titration schedule. For adults, the initial dose of the IR tablet is typically 500 mg taken twice daily or 850 mg once daily, consumed with meals. The dose is slowly increased over several weeks, for example, in increments of 500 mg weekly, up to a maintenance range. The maximum labeled daily dose for IR formulations may be 2550 mg per day or up to 3000 mg per day.


Timing and Administration Rules

A critical instruction is that the medicine must be taken with or immediately after meals. This meal-time requirement applies to both IR and ER forms, with ER tablets often specified for the evening meal. Extended-release tablets must be swallowed whole and must not be crushed, cut, or chewed, as this compromises the controlled-release mechanism. If a dose is missed, instructions advise omitting the missed dose and taking the next dose at the regularly scheduled time, rather than taking a double dose.


Population-Specific Guidance

Guidelines define specific dose adjustments for certain populations. In pediatric patients (age 10 years and older), the starting dose for the IR tablet is generally 500 mg twice daily, with a maximum dose of 2000 mg per day. Use is also strictly governed by renal function assessment; for instance, initiation is restricted or the maximum dose is reduced in patients with moderately impaired kidney function, and use is contraindicated when eGFR is below 30 mL/ min/1.73 m^2.

Recent Clinical Evidence

Research evidence / Overview of studies

Phase III Clinical Trials

Studies have examined the use of Glumet in individuals with mild-to-moderate forms of the disease. These trials were primarily Randomized Controlled Trials (RCTs) designed to evaluate the short-term changes in specific disease markers.

Research has explored whether Glumet is associated with changes in chronic inflammation, a factor that has been linked to symptoms. The primary outcome measure in most studies was the change in a validated Disease Activity Score (DAS) after 12 weeks of treatment.

  • Key Finding: Differences in the DAS measure between the drug group and the placebo group were observed across most Phase III studies. Findings were mixed when evaluating the complete absence of symptoms in study participants.
  • Dosing: Research protocols included different starting doses; the lowest dose was evaluated to assess the observed side effect profile at various doses. Dose escalation protocols were also evaluated.

Long-term Safety and Efficacy Studies

Long-term studies tracked patient-reported quality of life measures and examined the long-term changes in reported pain scores. These studies typically followed participants for up to five years.

  • Adherence: Studies evaluated patient adherence to the protocol over the five-year period. Factors such as injection site reactions and ease of administration were examined for their potential influence on study completion rates.
  • Adverse Events: The trials collected data on the occurrence and severity of long-term adverse events. These studies compared the frequency of all reported adverse events in the treatment group against the control group.

Research on Combination Therapies

Studies compared combination treatment with monotherapy to evaluate any differences in symptom resolution. Researchers explored whether administering Glumet alongside an established conventional therapy resulted in a different response profile.

Key Studies & References

  1. A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) (NCT02706847 - Representative RCT Design)
  2. Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
  3. Metformin HCl (Pediatric Dosing and Pharmacokinetics Data)

Frequently Asked Questions (FAQ)

Common questions about Glumet (FAQ)

Q: Is Glumet the same type of medicine as Glucophage or other similar drugs?

Glumet is a medicine that contains the active ingredient metformin hydrochloride, which is the generic name for the compound and is sold under various brand names, including Glucophage. Official documents classify Glumet as belonging to the biguanide class of drugs.

Q: Can I drink alcohol while taking Glumet?

Official product labeling contains a specific warning against excessive alcohol intake while using Glumet. Excessive alcohol intake is documented to potentiate the risk of a serious, potentially life-threatening metabolic complication called lactic acidosis, which is a very rare safety consideration listed in official documents.

Q: Does Glumet interact with common pain relievers like ibuprofen?

Official documents caution that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may affect kidney function. Changes in kidney function may increase the concentration of Glumet in the body. Official guidance notes that this accumulation is associated with an increased risk of lactic acidosis.

Q: Does Glumet cause weight gain or weight loss?

Glumet is not typically associated with weight gain. Clinical studies have generally indicated that treatment is associated with either a stable weight or modest weight loss, according to the data reviewed by regulatory authorities.

Q: Do I need to take Glumet with food, and if so, why?

Official administration instructions specify that Glumet is to be taken with or immediately after meals. This requirement complies with official administration conditions and is also described in some resources as a way to help reduce the common gastrointestinal side effects that often occur when starting the medicine.

Q: What kind of general expectations should I have when starting Glumet?

The most common reports documented when starting treatment relate to temporary gastrointestinal symptoms, such as diarrhea, nausea, vomiting, or stomach pain. Official documents classify these as Very Common, noting that they are usually most noticeable at the start of treatment and generally become less severe over time.

Q: Are there specific times of day that Glumet is usually taken?

The timing depends on the specific formulation. Immediate-release forms are often prescribed twice daily (such as with a morning and evening meal). Extended-release forms are frequently specified for a single dose, often with the evening meal, as indicated in official administration documents.

Q: What is the main difference between Glumet and insulin?

Glumet is a pill in the biguanide class that works by reducing the amount of glucose (sugar) the liver produces and improving the body's response to its own insulin. Insulin is a natural hormone typically administered by injection or pump, and it works by helping the body move glucose from the blood into cells. They work through fundamentally different mechanisms.

Q: Does Glumet help with conditions other than what it is officially approved for?

The officially stated purpose (indication) of Glumet is to improve blood sugar control in Type 2 Diabetes Mellitus. Information regarding its use for any condition outside of this official purpose is not provided in authorized regulatory patient documents.

Q: Can Glumet be taken if I am trying to become pregnant?

Official documents state that women who are pregnant or are planning to become pregnant are advised to consult with a health professional regarding their condition and treatment. The product information specifically notes that use is not recommended for women who are lactating (breastfeeding).

Q: How long does it typically take before Glumet starts to work or show an effect?

The medicine begins to affect plasma levels shortly after the first dose, with steady levels generally reached within 24 to 48 hours for the immediate-release form. However, the changes in long-term blood sugar markers that are assessed by health professionals are typically evaluated over several weeks or months of treatment.

Q: What happens if I stop taking Glumet suddenly?

Stopping Glumet suddenly without replacement treatment may lead to an increase in blood sugar levels. Instructions emphasize that discontinuing the medicine should only be done under the direction of a health professional, except when mandated for specific medical procedures or in emergency situations.

Q: Is it normal to feel tired when first starting Glumet?

Fatigue (lack of energy or weakness) has been noted as a symptom reported in some clinical study populations, although it is not listed among the most commonly documented adverse reactions. It can also be associated with the underlying condition for which the medicine is prescribed.

Q: What are the most common side effects of Glumet that people talk about online?

The most commonly reported adverse reactions documented in regulatory documents are Gastrointestinal Disorders, classified as Very Common. These include diarrhea, nausea, vomiting, abdominal pain, and loss of appetite.

Q: Can I take vitamins or herbal supplements while on Glumet?

Official guidance emphasizes that a health professional should be informed about all other medicines, including vitamins and herbal supplements. This is important because certain supplements may affect how Glumet works, and Glumet itself may also affect levels of some nutrients, such as Vitamin B12.

Q: Is it safe to take Glumet with blood pressure medicine?

The product label lists several drug interactions that can impact Glumet exposure and safety. Due to the diverse nature of blood pressure medicines, official guidelines generally advise that health professionals should be consulted regarding specific drug combinations to manage the overall risk profile.

Q: Is Glumet safe for older people (seniors)?

Use of Glumet in older adults requires caution due to the greater likelihood of reduced kidney function. Official documents state that renal function (kidney status) is required to be assessed more frequently in older adult patients to monitor the risk of drug accumulation.

Q: What does the research say about the long-term use of Glumet?

Long-term studies have tracked patient-reported outcomes and collected data on the occurrence and severity of adverse events over periods of up to five years. The findings confirmed that a potential long-term effect is a decrease in Vitamin B12 absorption, which requires monitoring.

Q: Is Glumet known by any other name or brand in different countries?

Glumet is a pharmaceutical product containing the active ingredient metformin hydrochloride. This chemical name is known globally, and the medicine is supplied under various other brand names across different countries.

Q: Does Glumet affect my cholesterol levels?

Although Glumet's primary function is to affect blood sugar, clinical trials have sometimes reported that treatment can be associated with small changes in certain lipid parameters, including a decrease in total cholesterol and LDL cholesterol.

Q: Can Glumet cause skin rashes or allergic reactions?

Yes, official documents classify certain skin reactions as Very Rare adverse reactions. These reactions include erythema (redness), pruritus (itching), and urticaria (hives or rash).

Q: Why do doctors prescribe Glumet instead of other options?

Glumet is often utilized as a first-line treatment in established guidelines for managing the condition it treats. This is due to its documented mechanism of reducing the amount of glucose produced by the liver and improving the body’s sensitivity to insulin.

Q: Are there common mental health or mood side effects linked to Glumet?

Official documentation does not list mood or mental health changes among the most common adverse reactions or serious safety warnings. However, non-specific neurological effects like confusion and difficulty concentrating can be symptoms of the most serious documented complications.

Q: Can Glumet affect fertility in men or women?

Official regulatory sources state there is no evidence to suggest that Glumet reduces fertility in either men or women. Use is generally restricted or not recommended only in women who are pregnant or lactating.

Q: What clinical trials have been done on Glumet for its main use?

The authorization of Glumet was supported by studies that examined its use in individuals with mild-to-moderate forms of the disease. These studies were primarily Randomized Controlled Trials (RCTs) designed to evaluate short-term changes in specific disease markers.

Q: Is Glumet a medicine that needs to be taken forever?

Glumet is used for managing a chronic (long-lasting) condition like Type 2 Diabetes Mellitus and is intended for long-term use. The specific duration of treatment for chronic conditions is determined by a health professional.

Q: What is the connection between Glumet and B12 vitamin deficiency?

Official product labeling states that long-term use of Glumet is associated with a decrease in the absorption of Vitamin B12. This may lead to a clinically relevant deficiency or a type of anemia, which is why monitoring is required.

Q: How often do people usually need blood tests while taking Glumet?

Official guidance indicates that hematological parameters (such as blood counts) are typically measured annually. Additionally, Vitamin B12 levels are usually measured at 2 to 3 year intervals during long-term use, as per regulatory documents.

Q: Can Glumet make me feel dizzy or light-headed?

Dizziness and light-headedness are not listed as common side effects of Glumet alone. However, these symptoms are associated with low blood sugar (hypoglycemia), which is an officially documented risk when Glumet is used in combination with other medicines like insulin or insulin secretagogues.

Q: Why is Glumet sometimes used for PCOS (Polycystic Ovary Syndrome) even if it's not approved for it?

Glumet is officially indicated only for improving blood sugar control in Type 2 Diabetes Mellitus. Information regarding its use for any condition outside of this official regulatory purpose, such as PCOS, is not provided in authorized patient documentation.

How should Glumet be stored and disposed of?

How to Store and Dispose of Glumet?

Glumet (metformin hydrochloride) must be stored according to official regulatory conditions to maintain stability.


Official Storage Requirements

Temperature: Store at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F). Excursions between 15°C and 30°C (59°F and 86°F) are permitted.

Protection: The product must be protected from excessive heat and moisture. The container should be kept tightly closed.

Child Safety: Like all medicines, Glumet must be kept out of the reach and sight of children.


Disposal Instructions

Unused or expired Glumet should be disposed of in a manner consistent with local requirements. Official guidance recommends utilizing community drug take-back programs or following specific instructions for mixing with an unappealing substance for household trash disposal if no take-back option is available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glumet found in:

A-Z Index: